On June 5, 2023 Papyrus Therapeutics Inc., an emerging biotechnology company pioneering the development of tumor suppressor restoration treatments for solid cancers, reported that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for multiple claims related to the company’s patent filings on unique design features for the development of a platform of novel tumor suppressor therapies for a variety of solid cancers (Press release, Papyrus Therapeutics, JUN 5, 2023, View Source;utm_medium=rss&utm_campaign=papyrus-therapeutics-notice-of-allowance-from-uspto-enhances-tumor-suppressor-therapy-ip-portfolio [SID1234632476]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This notice of allowance provides further validation of Papyrus’ novel approach to treat cancers with our lead OPCML candidate, PYTX-004, a unique recombinant protein that restores the natural tumor suppression in over 40% of solid tumors," said Dr. Paul Blake FRCP, CEO of Papyrus Therapeutics. "These patents represent a critical step in protecting our technology, expanding our therapeutic platform, and establishing Papyrus Therapeutics as the leader in novel tumor suppressor treatments."
About OPCML and PYTX-004
OPCML is a normally expressed potent tumor suppressor protein that is lost during cancer development and it works by binding to the external leaflet of the cancer cell membrane. PYTX-004 is a Fc-fused form of OPCML that is designed to suppress tumor growth and demonstrate circulating characteristics of an antibody to enable IV use.
Papyrus Therapeutics’ PYTX-004
PYTX-004 inhibits the MEK-ERK and PI3K-AKT pathways as part of its potent tumor suppressor action. As such, PYTX-004 is not an RTK inhibitor, it is a native engineered protein replacement that is anticipated to be a well tolerated treatment as it targets only cancer cells without damaging healthy cells, unlike chemotherapy.